MIRA Pharmaceuticals, Inc. announced it has completed the acquisition of SKNY Pharmaceuticals, Inc., expanding its drug development pipeline to include SKNY-1, a next-generation oral therapy candidate for obesity and nicotine addiction. As part of the transaction, SKNY contributed $5 million in marketable securities to MIRA, strengthening the company's financial position. According to MIRA, SKNY-1 is designed to modulate CB1, CB2, and MAO-B pathways to address energy storage, lipid metabolism, appetite, cravings, and reward, while avoiding the psychiatric side effects seen with earlier CB1-targeting drugs. Preclinical findings highlight up to a 30% reduction in body weight without muscle loss, improved metabolic parameters, and reversal of nicotine and high-calorie food cravings. The acquisition also complements MIRA's ongoing programs, including Ketamir-2 for neuropathic pain and MIRA-55 for inflammatory pain. MIRA Pharmaceuticals stated the expansion positions the company to address major unmet medical needs across several large healthcare markets.